Back to Results
First PageMeta Content
Myelofibrosis / Essential thrombocytosis / Myeloproliferative disease / Plateletpheresis / Ruxolitinib / Megakaryocyte / Platelet / Bone marrow / Anemia / Medicine / Biology / Anatomy


Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard
Add to Reading List

Document Date: 2015-02-08 17:25:15


Open Document

File Size: 2,49 MB

Share Result on Facebook
UPDATE